Acute monocytic leukemia
MONDO:0007896Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
Also known as: monocytic leukaemia, monocytic leukemia, AML M5, acute monoblastic leukaemia and acute monocytic leukaemia, acute monocytic leukaemia (FAB M5B), acute monocytic leukaemia (FAB M5b), acute monocytic leukemia, acute monocytic leukemia (FAB M5B)
2868 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1324 trials in this tab.
-
New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to …
Phase: PHASE1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control Recruiting nowThis early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…
Phase: EARLY_PHASE1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase: PHASE1, PHASE2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New experimental drug BMS-986500 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Tailor-Made vaccine aims to train immune system against cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Cancer patients get continued access to promising drugs in new safety trial
Disease control Recruiting nowThis study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and maraviroc) can safely prevent graft-versus-host disease after a half-matched bone marrow transplant in people living with HIV who also have a blood cancer. The trial involves 265 participants…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase: PHASE1, PHASE2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New targeted pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on peop…
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for tough leukemia: first human trial of KK2845 begins
Disease control Recruiting nowThis early-stage study tests a new drug called KK2845 for adults whose acute myeloid leukemia (AML) has returned or not improved after standard treatments. The goal is to find a safe dose and see how well the body tolerates it. About 72 participants will take part in two phases: …
Phase: PHASE1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IPN01195 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New transplant cocktail aims to tame blood cancer without severe side effects
Disease control Recruiting nowThis early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …
Phase: PHASE1 • Sponsor: Sawa Ito, MD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could old drugs beat rare cancers? new trial aims to find out
Disease control Recruiting nowThe DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a tailored quit-smoking program help cancer patients and survivors kick the habit for good?
Disease control Recruiting nowThis study explores how to best help cancer patients, survivors, and their caregivers quit tobacco. Participants can choose between group or one-on-one counseling sessions. The goal is to see if this program is practical and well-received, paving the way for better tobacco cessat…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for tough blood cancers enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill for Hard-to-Treat cancers enters first human tests
Disease control Recruiting nowThis early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…
Phase: PHASE1 • Sponsor: Degron Therapeutics Co. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced cancers? early trial of PYX-201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…
Phase: PHASE1 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug duo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug E303 enters human trials
Disease control Recruiting nowThis early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …
Phase: PHASE1 • Sponsor: Samsung Bioepis Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Old antibiotic, new hope: novobiocin targets Cancer's weak DNA repair
Disease control Recruiting nowThis early-phase trial tests an antibiotic called novobiocin in people with advanced solid tumors that have specific DNA repair mutations (like BRCA). The drug blocks a protein cancer cells use to fix their damaged DNA, which may cause them to die. The study aims to find the safe…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced cancer: LBL-024 trial now recruiting
Disease control Recruiting nowThis study is testing an experimental drug called LBL-024 in people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 396 adults aged 18 to 80 are taking part. The drug is given…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase: PHASE2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to shield blood cancer patients from Post-CAR-T infections
Disease control Recruiting nowThis study tests whether giving antibody replacement therapy can reduce serious infections in people who have received CAR-T cell therapy for blood cancers. CAR-T therapy often lowers the body's natural antibodies, raising infection risk. The trial will compare the antibody treat…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Scientists combine CAR t therapy and bone marrow transplant to attack tough blood cancers
Disease control Recruiting nowThis early-phase trial tests whether giving anti-CD19 CAR T cells together with a half-matched bone marrow transplant can safely treat aggressive blood cancers like leukemia and lymphoma. About 155 adults aged 18 to 75 with CD19-positive cancers will receive the combined therapy …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo takes on tough tumors
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New immune drug STK-012 takes on tough lung cancers
Disease control Recruiting nowThis study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cancer combo enters early human testing
Disease control Recruiting nowThis early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests whether adding the drug belumosudil to standard care can better prevent graft-versus-host disease (GVHD) in adults with blood cancer who have had a stem cell transplant. About 46 participants will receive belumosudil along with their usual GVHD prevention medicin…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-0015 begins
Disease control Recruiting nowThis early-stage trial tests a new oral drug called ERAS-0015, alone or with other cancer drugs, in 600 adults with advanced solid tumors that have certain RAS mutations. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Researc…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Keytruda's Long-Term safety under the microscope in massive cancer trial
Disease control Recruiting nowThis study is checking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in 3500 people with various solid tumors or blood cancers. Participants are moving from earlier Merck studies into this one, continuing their treatment or follow-up. The goal…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Spinal chemotherapy may stop brain damage from cancer treatment
Disease control Recruiting nowThis phase 2 trial tests whether injecting chemotherapy drugs (cytarabine, methotrexate, and hydrocortisone) into the spinal fluid can prevent severe brain side effects in people receiving CAR T-cell therapy for blood cancers. About 20-70% of CAR T patients develop neurotoxicity,…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New smart drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis trial tests a new drug called DS3790a for people with certain blood cancers, including B-cell non-Hodgkin lymphoma. The drug is designed to find and attack cancer cells while sparing healthy ones. The study will check safety and how well it works in about 420 adults.
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase: PHASE2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer pill SNV1521 enters human testing
Disease control Recruiting nowThis early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.
Phase: PHASE1 • Sponsor: Synnovation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug TQB3142 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called TQB3142 in 66 adults with advanced tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look f…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug XTX301 takes on advanced cancers in first human trial
Disease control Recruiting nowThis study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New combo aims to reboot immunotherapy in resistant cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer antibody ONC-841 enters human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…
Phase: PHASE1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase: PHASE1, PHASE2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Warm during surgery? new trial tests if temperature control boosts survival in older cancer patients
Disease control Recruiting nowThis study tests whether carefully managing body temperature during major cancer surgery can lower the risk of postoperative delirium (sudden confusion) and improve long-term survival in patients aged 65 and older. About 4,000 participants will be randomly assigned to either rout…
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug called XB628, alone or with an oral drug called zanzalintinib, in people with advanced or metastatic solid tumors that have not responded to prior treatments. The study has two parts: first, finding a safe dose, and then check…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
MRNA vaccine technology takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…
Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental cancer drug enters human testing
Disease control Recruiting nowThis early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug RSC-1255 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental drug called RSC-1255, given alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The study has two parts: first, finding a safe dose, and …
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers with specific gene mutation
Disease control Recruiting nowThis study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…
Phase: PHASE1, PHASE2 • Sponsor: Ensem Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New enzyme shot takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…
Phase: PHASE1, PHASE2 • Sponsor: Onchilles Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis phase 2 trial is testing a drug called calderasib (MK-1084), given alone or with cetuximab, in 150 people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the cancer shrinks or disappears and to check for side effects. Participants mu…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control Recruiting nowThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill targets Hard-to-Treat cancers with hippo pathway mutations
Disease control Recruiting nowThis study tests a new drug called SW-682, taken as a tablet, for people with advanced solid tumors that have not responded to standard treatments. The trial focuses on tumors with changes in the Hippo pathway, including mesothelioma. In the first part, doctors will find the safe…
Phase: PHASE1 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Supercharged immune cells take on cancer in new trial
Disease control Recruiting nowThis study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug ZL-6201 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.
Phase: PHASE1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can a coordinated care program boost quality of life for cancer patients facing social hardships?
Disease control Recruiting nowThis study tests a program called Comprehensive Connected Cancer Care (C4) for people newly diagnosed with cancer who also have social needs (like trouble paying for medicine or getting to appointments). The program uses patient navigators, a digital needs assessment, and better …
Phase: NA • Sponsor: Timothy Mullett • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug YL201 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called YL201 in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then testing that dose in more patients with specific cancer types. YL201 is given by IV every t…
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C137, which delivers chemotherapy directly to cancer cells that have a specific marker (FGFR2b). The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have run out of standard options. Abo…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AO-252 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…
Phase: PHASE1 • Sponsor: A2A Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…
Phase: PHASE1 • Sponsor: Chiome Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial matches cancer patients to smart drug bombs
Disease control Recruiting nowThis phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to shrink hard-to-treat cancers
Disease control Recruiting nowThis study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug H1710 enters first human tests
Disease control Recruiting nowThis early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …
Phase: PHASE1 • Sponsor: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase: EARLY_PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for cancer patients with autoimmune conditions: immune checkpoint inhibitor trial expands access
Disease control Recruiting nowThis study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Fighting viruses take on advanced tumors in early trial
Disease control Recruiting nowThis phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and to understand side effects. About 66 participants wi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced cancer? first human trial of BNT3212 begins
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radiation treatment shows promise for cancer patients
Disease control Recruiting nowThis study is testing a new type of radiation therapy called DaRT for people with malignant tumors. The main goal is to see how safe the treatment is and what side effects occur. Researchers will also check if the tumors shrink three months after treatment. About 100 adults with …
Phase: NA • Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug OVV-01 injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…
Phase: PHASE1 • Sponsor: Joint Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PARP1 inhibitor IMP1734 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug STP938 tested in patients with incurable cancers
Disease control Recruiting nowThis early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…
Phase: PHASE1 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic drug CM518D1 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…
Phase: PHASE1, PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug BAL0891 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Tailored drug dosing may cut infections after stem cell transplants
Disease control Recruiting nowThis study tests whether giving anti-thymocyte globulin (ATG) based on individual patient levels can reduce viral infections after stem cell transplants from unrelated donors. About 324 patients will receive either personalized or fixed doses of ATG. The goal is to find a dose th…
Phase: PHASE4 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Phase: NA • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Cancer drug pelabresib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…
Phase: PHASE1, PHASE2 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug AN8025 tested in patients with advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug MG2512 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called MG2512 in about 116 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also w…
Phase: PHASE1 • Sponsor: Shanghai Mabgen Biopharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New radiation method targets tough tumors
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…
Phase: PHASE2 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…
Phase: PHASE1, PHASE2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Targeted pill aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New trial aims to give every blood cancer patient a donor
Disease control Recruiting nowThis early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the …
Phase: PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug ADCX-020 enters first human trials for advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find th…
Phase: PHASE1 • Sponsor: Adcytherix SAS • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets rare genetic cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New chemo injection targets tumors directly in early trial
Disease control Recruiting nowThis early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…
Phase: PHASE1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to control hard-to-treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug called BL-M24D1 in about 33 adults with multiple myeloma or other blood cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps control the disease. Particip…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shows promise for Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …
Phase: PHASE2, PHASE3 • Sponsor: SUNHO(China)BioPharmaceutical CO., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New targeted cancer drug STX-478 enters human trials
Disease control Recruiting nowThis study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a new cancer drug, repotrectinib, combined with standard chemotherapy in children and young adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Researchers will also study how the b…
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New immune drug OSE-279 takes on advanced tumors
Disease control Recruiting nowThis study tests a new drug called OSE-279 that helps the immune system fight cancer. It is for people with advanced solid tumors or lymphomas that have not responded to other treatments. The trial has three parts: finding the right dose, checking safety, and measuring how well t…
Phase: PHASE1, PHASE2 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cancer drug combo trial launches for Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…
Phase: PHASE1 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Cancer-Fighting virus injected into tumors shows promise in early trial
Disease control Recruiting nowThis early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…
Phase: PHASE1 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…
Phase: PHASE1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental blood cancer drug KK2430 enters first human tests
Disease control Recruiting nowThis study is the first time the experimental drug KK2430 is being tested in humans. It aims to find out if KK2430 is safe, how the body processes it, and whether it can help treat blood cancers. About 72 adults with blood cancers that have not responded to other treatments will …
Phase: PHASE1, PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill shows promise in early cancer trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New Antibody-Drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD5335, alone or with other cancer medicines, in people with advanced solid tumors like ovarian, lung, and endometrial cancers. The goal is to see if the drug is safe, tolerable, and shows signs of shrinking tumors. About 506 participants will …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New experimental drug HS-20108 enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…
Phase: PHASE1 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New transplant approach aims to fight blood cancers with fewer side effects
Disease control Recruiting nowThis early-phase study tests a new way to give immune cells (T-cells) after a stem cell transplant in children with high-risk blood cancers. The goal is to see if giving special memory T-cells early can help fight cancer while reducing dangerous side effects like graft-versus-hos…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill shows promise for rare blood cancers in early trial
Disease control Recruiting nowThis study tests a new daily pill called JBI-802 in people with certain blood cancers (myeloproliferative neoplasms and MDS/MPN) who have too many platelets. The trial has two phases: first, finding a safe dose in about 30 adults, then checking if it works. Participants take the …
Phase: PHASE1, PHASE2 • Sponsor: Jubilant Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Nanoparticle drug aims to wake up immune system against tumors
Disease control Recruiting nowThis study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…
Phase: PHASE1, PHASE2 • Sponsor: United Immunity, co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug IACS-6274 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…
Phase: PHASE1 • Sponsor: SEED Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets Hard-to-Treat cancers with a specific gene mutation
Disease control Recruiting nowThis study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for kids with tough tumors: drug combo trial launches
Disease control Recruiting nowThis study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals a…
Phase: PHASE1, PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control Recruiting nowThis study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to shield heart while fighting tumors
Disease control Recruiting nowThis early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…
Phase: PHASE1 • Sponsor: Racura Oncology Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug SBO-154 enters human testing for advanced tumors
Disease control Recruiting nowThis early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…
Phase: PHASE1 • Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New bone marrow transplant trial offers hope for kids with severe blood disorders
Disease control Recruiting nowThis study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug hope for patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug INV-6452 targets Hard-to-Treat breast cancers
Disease control Recruiting nowThis study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…
Phase: PHASE1, PHASE2 • Sponsor: Crossignal Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for cancer patients: experimental drug aims to stop dangerous blood clots
Disease control Recruiting nowThis study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can your Cancer's genes pick the right drug? TAPUR study aims to find out
Disease control Recruiting nowThe TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…
Phase: PHASE2 • Sponsor: American Society of Clinical Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to fight advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 particip…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to stop transplant rejection in blood cancer patients
Disease control Recruiting nowThis study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and abatacept) can prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancers. About 74 adults will take part. The goal is to reduce severe immune react…
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug ERX-315 enters first human tests for tough cancers
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…
Phase: PHASE1 • Sponsor: EtiraRx Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New study checks if kidney disease affects cancer drug safety
Disease control Recruiting nowThis early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for Hard-to-Treat cancers: experimental drug BMS-986523 enters human trials
Disease control Recruiting nowThis study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New combo aims to revive immunotherapy in resistant cancers
Disease control Recruiting nowThis early-stage trial tests whether adding a chemotherapy drug (5-Azacitidine) to standard immunotherapy can help patients whose solid tumors have stopped responding to PD-1/PD-L1 inhibitors. About 35 adults with advanced or metastatic cancers will receive the combination to fin…
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Chilling out to fight cancer: cold therapy meets immunotherapy in new trial
Disease control Recruiting nowThis early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for advanced cancer: first human trial of GS-0201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cancer drug HLX316 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…
Phase: PHASE1, PHASE2 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to prevent transplant complications
Disease control Recruiting nowThis study tests whether switching to the drug ruxolitinib after a stem cell transplant can better prevent chronic graft-versus-host disease (GVHD) compared to standard treatment. About 40 adults with blood cancers who are in remission will receive either a medium dose of cycloph…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug enters early human testing for advanced solid tumors
Disease control Recruiting nowThis early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
Disease control Recruiting nowThis early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced cancer: first human trial of ALK201 begins
Disease control Recruiting nowThis study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for hard-to-treat cancers: combo drug trial launches
Disease control Recruiting nowThis study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New Antibody-Drug conjugate targets advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New gene therapy targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart shield for young cancer survivors: new study tests dexrazoxane
Disease control Recruiting nowThis study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…
Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New antibody AU-007 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…
Phase: PHASE1, PHASE2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for advanced cancer patients: SKB103 trial now recruiting
Disease control Recruiting nowThis study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cancer drug SHR-4506 enters first human tests
Disease control Recruiting nowThis early-stage study tests a new injection called SHR-4506 in 102 adults with advanced malignant tumors who have run out of standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the disease. Participants must …
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cancer drug AMT-676 enters first human tests
Disease control Recruiting nowThis early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…
Phase: EARLY_PHASE1 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug targets cancer DNA in advanced tumors
Disease control Recruiting nowThis early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot…
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for advanced cancers? first human trial of DS5361b begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Experimental ‘In vivo’ CAR-T therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called V001 Injection, which aims to create cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to chec…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Engineered T-Cells take on recurrent solid tumors in new trial
Disease control Recruiting nowThis study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…
Phase: PHASE1, PHASE2 • Sponsor: Immatics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New DNA drug targets advanced cancer and wasting
Disease control Recruiting nowThis early-phase trial tests a new drug called SXRN, made from DNA, in 28 people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find the right dose, while also seeing if it helps with appetite and physical function. The stu…
Phase: EARLY_PHASE1 • Sponsor: Jiangsu Nutai Biologics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
5-Drug cocktail takes on tough cancers in new trial
Disease control Recruiting nowThis study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…
Phase: PHASE1, PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…
Phase: PHASE1 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug TAK-243 targets cancer cells in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called TAK-243 in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and check for side effects. TAK-243 works by blocking a protein that cancer cells need t…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…
Phase: PHASE1 • Sponsor: Jun Zhou • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug PEEL-224 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…
Phase: PHASE1 • Sponsor: Peel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced cancer: first human trial of SIGX1094R begins
Disease control Recruiting nowThis early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…
Phase: PHASE1 • Sponsor: Signet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental injection targets tumors directly in new cancer trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…
Phase: PHASE1 • Sponsor: Vaxiion Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Extended drug regimen may shield transplant patients from deadly immune attack
Disease control Recruiting nowThis study tests whether giving more doses of the drug abatacept over a longer period can better prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body. About 160 people receiving stem cell transplants from partially ma…
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immune cell 'Packages' injected into tumors: a new hope for advanced cancer?
Disease control Recruiting nowThis early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for advanced cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New scan technique could sharpen tumor targeting during radiation
Diagnosis Recruiting nowThis study tests whether a special CT scan with contrast dye can give clearer images of tumors during radiation therapy. Twenty adults with advanced cancer will receive the extra scan alongside their standard treatment. The goal is to see if this approach is feasible and improves…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New imaging tracer could spot tumors more clearly
Diagnosis Recruiting nowThis early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New scan could spot hidden cancers better
Diagnosis Recruiting nowThis early-phase study tests a new radioactive tracer called FAP-2286 to see how well it can detect cancer that has spread in adults with solid tumors. About 191 participants will receive the tracer and then have a PET scan. The goal is to measure safety and how clearly the trace…
Phase: PHASE1 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
New scan could reveal hidden cancers in PD-L1 patients
Diagnosis Recruiting nowThis study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…
Sponsor: Tianjin Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New MRI scan could reveal Cancer's true aggressiveness
Diagnosis Recruiting nowThis study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Robert Bok, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New PET tracer aims to spot hidden cancers
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called 18F-FGln, which targets glutamine—a nutrient that cancer cells need to grow. Researchers want to see if PET/CT scans using this tracer can more accurately detect and stage various cancers, especially those that are hard to see…
Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New PET tracer aims to reveal hidden inflammation in cancer patients
Diagnosis Recruiting nowThis early-stage study tests a new imaging agent called 18F-4FN for PET scans to safely detect inflammation in the body. It involves 55 adults with cancer who are on immunotherapy or have suspected inflammation. The goal is to see if this agent can highlight areas of inflammation…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
Simple blood test could spot multiple cancers early
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…
Sponsor: Chang Gon Kim • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New PET tracer could spot hidden cancers
Diagnosis Recruiting nowThis study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive t…
Sponsor: First Hospital of China Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
Could a simple scan replace biopsies for key cancer marker?
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 68Ga-NK224 that lights up PD-L1, a protein on cancer cells, during a PET/CT scan. Researchers want to see if the scan can accurately measure PD-L1 levels compared to standard tissue biopsy. One hundred adults with various cancers w…
Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New blood test could spot multiple cancers before symptoms appear
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…
Sponsor: ClearNote Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Mouthwash may stop chemo mouth sores in their tracks
Prevention Recruiting nowThis study tests whether a dexamethasone mouthwash can prevent moderate to severe mouth sores caused by chemotherapy in adults with cancer. Participants use the mouthwash four times daily during chemo for up to 8 weeks. Researchers compare their outcomes to a historical group to …
Phase: PHASE4 • Sponsor: Woman's • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Dental cleaning may ward off deadly transplant complication
Prevention Recruiting nowThis study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Cooling sleeve could shield cancer patients from chemo nerve pain
Prevention Recruiting nowThis study tests a special cooling and compression sleeve (Paxman Limb Cryocompression System) worn during chemotherapy to prevent nerve damage, a common side effect. About 200 cancer patients receiving weekly paclitaxel will use the device for up to 4 hours per session. Research…
Phase: NA • Sponsor: National University Hospital, Singapore • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Cheap statin could slash deadly clot risk in cancer patients
Prevention Recruiting nowThis study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Online resilience training aims to ease anxiety in advanced cancer
Symptom relief Recruiting nowThis study tests a virtual group program designed to help people with advanced cancer build resilience and manage stress, anxiety, and fatigue. Participants attend seven weekly online sessions that teach techniques like mindfulness, gratitude, and reframing difficult experiences.…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Cancer patients' values take center stage in new nurse-led program
Symptom relief Recruiting nowThis study adapts a program called CONVO for Spanish-speaking Latinx adults with solid tumors. In the program, nurses talk with patients about their personal values during routine cancer care. The goal is to make care more respectful and supportive. About 234 adults will take par…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jul 03, 2026 23:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief Recruiting nowThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief Recruiting nowThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief Recruiting nowThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
New app aims to make End-of-Life conversations easier for cancer patients
Symptom relief Recruiting nowThis study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to …
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could eating only during daylight hours improve cancer treatment?
Symptom relief Recruiting nowThis study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Allergy drug and supplement face off in battle against cancer treatment bone pain
Symptom relief Recruiting nowThis study tests two oral medications—diosmin-hesperidin (a flavonoid supplement) and loratadine (an allergy drug)—to prevent bone pain caused by G-CSF, a drug that boosts white blood cells in blood cancer patients. Researchers will compare each drug alone and in combination agai…
Phase: NA • Sponsor: Alexandria University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can phone Check-Ins ease cancer treatment side effects?
Symptom relief Recruiting nowThis study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…
Phase: NA • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Virtual meditation may ease cancer stress in rural areas
Symptom relief Recruiting nowThis pilot study tests whether a virtual mindfulness-based stress reduction (MBSR) program can improve mental health in cancer patients living in underserved or rural parts of Minnesota. About 45 participants will take the online course and report changes in stress, anxiety, and …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a special diet soothe chemo nerve damage?
Symptom relief Recruiting nowThis study tests whether a diet low in added sugar, high in fiber, and rich in omega-3s (called LASO-3) can help reduce nerve pain, numbness, and tingling caused by chemotherapy. Fifty cancer survivors who finished chemo at least three months ago will receive virtual nutrition co…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Step up: a new program aims to boost daily steps and reduce disability in blood cancer survivors.
Symptom relief Recruiting nowThis study tests a program called Step Up that combines in-person coaching with a mobile app to teach coping skills and encourage physical activity. It includes 177 adults who have had a stem cell transplant or CAR-T therapy for blood cancers like leukemia or multiple myeloma. Th…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Can a phone or video chat lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a type of talk therapy called behavioral activation (BA) can help treat depression in older adults who have survived cancer. Participants will receive BA or supportive psychotherapy remotely via video or phone over 10 weeks. The goal is to see if BA reduc…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief Recruiting nowThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Weighted blankets may ease anxiety for cancer patients during IV therapy
Symptom relief Recruiting nowThis study looks at whether using a weighted blanket during intravenous cancer treatment can help lower anxiety, stress, and depression, and improve comfort. About 152 adults with solid cancers who are starting their first IV therapy will be randomly assigned to receive either a …
Phase: NA • Sponsor: Sultan Qaboos Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New support program hopes to ease Cancer's toll on chinese patients
Symptom relief Recruiting nowThis study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Hearing loss shield: new drug may protect ears during chemo
Symptom relief Recruiting nowThis study tests a drug called Pedmark (sodium thiosulfate) to see if it can prevent hearing loss in adults receiving cisplatin chemotherapy for cancers like testicular, head and neck, or thoracic cancer. About 25 adults will take Pedmark alongside their chemo. The drug is alread…
Phase: PHASE1, PHASE2 • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study trains therapists to tackle Cancer's hidden toll: anxiety, pain, and insomnia
Symptom relief Recruiting nowThis study aims to train psychotherapists to deliver personalized, evidence-based therapies to cancer patients and their caregivers who are experiencing high levels of distress. Therapists will choose from treatments like cognitive behavioral therapy and mindfulness-based stress …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Cancer care goes home: study tests nurse visits to cut hospital trips
Symptom relief Recruiting nowThis study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New app aims to ease cancer distress
Symptom relief Recruiting nowThis study tests whether a mobile app called Tools for Coping with Cancer can help people with a history of cancer reduce distress and improve mood and quality of life. About 50 adults who have had cancer will use the app at home for 8 weeks and fill out questionnaires about thei…
Phase: NA • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can a smartphone app lift depression in cancer survivors?
Symptom relief Recruiting nowThis study compares two ways to treat depression in cancer survivors: a mobile app called Moodivate that tracks activities and mood, and 8 sessions of telehealth therapy with a mental health provider. About 45 adults who have had cancer and currently feel depressed will take part…
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
New support program aims to help cancer patients finish treatment and feel better
Symptom relief Recruiting nowThis study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Squeeze away chemo pain: gloves and boots may stop nerve damage
Symptom relief Recruiting nowThis study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…
Phase: NA • Sponsor: Luminate Medical, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New program aims to smooth cancer Patients' return home
Symptom relief Recruiting nowThis study tests a program to help cancer patients transition from hospital to home. It includes a meeting with a nurse before leaving, an app to report symptoms, and a follow-up phone call. The goal is to see if this approach is feasible and improves patient satisfaction and qua…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New program aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New radiation technique may ease cancer bone pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial tests whether a precise, high-dose radiation technique (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases not in the spine. About 230 adults with solid tumors and moderate to severe pain will be randomly …
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New program aims to boost resilience in young cancer patients
Symptom relief Recruiting nowThis study is testing a support program for teens and young adults (ages 16-30) who have just been diagnosed with cancer. The program includes a meeting with a special team and a structured course called PRISM that teaches skills like stress management and goal setting. About 130…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase: PHASE1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can talking about stress ease Cancer's mental toll? new study aims to find out
Symptom relief Recruiting nowThis study tests whether group sessions that teach stress management skills can lower distress in people with cancer. About 400 adults with cancer who have moderate distress will take part. The program helps patients recognize and reduce stress in their daily lives.
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
VR gives hospitalized kids with cancer a fun way to get moving
Symptom relief Recruiting nowThis study tests whether virtual reality (VR) can help children and young adults with cancer be more physically active while in the hospital. 40 participants aged 10-25 will try both VR-assisted physical therapy and traditional physical therapy to see which one gets them moving m…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can a website help young cancer survivors with sexual health? a new study aims to find out.
Symptom relief Recruiting nowThis study tests a web-based program called OMGYES.com to see if it helps young adult female cancer survivors who have sexual problems. About 30 people will take part, using online modules at home and visiting the clinic every 5 weeks for questionnaires. The goal is to see if the…
Phase: NA • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Time-Restricted eating may beat cancer fatigue, new study hopes
Symptom relief Recruiting nowThis study tests whether eating all food within a 10-hour window each day can reduce severe, long-lasting fatigue in blood cancer survivors. About 96 adults who finished cancer treatment at least 2 months ago will either follow this time-restricted eating plan or receive standard…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New study aims to ease cancer journey for LGBTQ+ patients and loved ones
Symptom relief Recruiting nowThis study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…
Phase: NA • Sponsor: Charles Kamen • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Writing away the worry: new study tests expressive writing for cancer survivors
Symptom relief Recruiting nowThis study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New IV combo aims to stop chemo sickness in kids
Symptom relief Recruiting nowChemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…
Phase: PHASE2 • Sponsor: Helsinn Healthcare SA • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase: PHASE2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Can spiritual care improve well-being for advanced cancer patients?
Symptom relief Recruiting nowThis study tests two types of spiritual care for people with advanced cancer. Researchers want to see if these programs improve spiritual well-being and reduce hospital visits. About 288 patients from religious communities will take part.
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Simple breathing and muscle relaxation techniques tested for cancer symptom relief
Symptom relief Recruiting nowThis study looks at whether two simple relaxation methods—progressive muscle relaxation and deep breathing exercises—can reduce shortness of breath and severe tiredness in people with advanced cancer receiving palliative care. About 90 participants will be assigned to one of the …
Phase: NA • Sponsor: Ankara University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New online tool aims to lift mood in cancer patients
Symptom relief Recruiting nowThis study tests an online program called My Wellbeing Guide for cancer patients who feel depressed or anxious. The program uses videos, activities, and written tips based on cognitive behavioral therapy over 7 weeks. About 6,500 participants will be randomly assigned to the prog…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Sniff away stress: aromatherapy stick tested for transplant patients
Symptom relief Recruiting nowThis study tests whether using an aromatherapy inhaler (with lavender or peppermint) can help reduce distress and improve coping for patients recovering from a stem cell transplant. About 50 adult patients will use the inhaler during their hospital stay. The goal is to see if thi…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can a walking program beat cancer fatigue?
Symptom relief Recruiting nowThis study tests a physical activity program designed for cancer survivors and their caregivers. About 164 adults who have finished cancer treatment (except hormone therapy or maintenance chemo) will take part. The goal is to see if the program improves physical function and redu…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can online therapy ease the mental toll of cancer? mayo clinic investigates
Symptom relief Recruiting nowThis study tests whether virtual group therapy based on Acceptance and Commitment Therapy (ACT) and compassion practices can improve psychological well-being in cancer patients. Researchers at Mayo Clinic will enroll 200 adults with cancer who are experiencing stress. Participant…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Phone coaching helps cancer patients have tough End-of-Life conversations
Symptom relief Recruiting nowThis study tests whether a telephone coaching program called Talking About Cancer (TAC) helps people with advanced cancer and their support person engage in advance care planning, such as having end-of-life conversations and completing advance directives. About 80 patients and th…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Finger pressure vs. fear: can acupressure ease chemo anxiety?
Symptom relief Recruiting nowThis study tests whether acupressure, a non-invasive technique using finger pressure on specific body points, can reduce anxiety in cancer patients receiving chemotherapy. Researchers will compare real acupressure to a sham (placebo) version in 78 adults with cancer. The goal is …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
New program aims to remove travel hurdles for cancer patients
Symptom relief Recruiting nowThis study tests a program called TRACT that helps cancer patients with travel to their radiation therapy appointments. Many patients miss or delay treatment due to transportation issues. The program provides navigation support and resources. Researchers will see if it is practic…
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Can a short DBT program help cancer patients kick the habit?
Symptom relief Recruiting nowThis study is testing a short group therapy program based on Dialectical Behavior Therapy (DBT) to help cancer patients reduce or stop smoking. The program focuses on building skills in emotion regulation, distress tolerance, and mindfulness. The trial will enroll 16 participants…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Fasting diet may ease immunotherapy side effects in cancer patients
Symptom relief Recruiting nowThis study tests whether a special low-calorie, plant-based diet that mimics fasting can reduce common side effects like rash, diarrhea, and fatigue in cancer patients receiving immunotherapy. Ten adults with advanced cancer will follow the diet and report their symptoms. The goa…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can music soothe cancer anxiety as well as talk therapy?
Symptom relief Recruiting nowThis study compares music therapy and cognitive behavioral therapy (CBT) for reducing anxiety in people who have had cancer. 368 cancer survivors with anxiety will receive seven weekly virtual sessions of either music therapy or CBT. Researchers will track anxiety levels over 26 …
Phase: PHASE4 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New coaching program aims to help young cancer survivors connect with friends
Symptom relief Recruiting nowThis study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New computer tool aims to help young cancer patients take control of symptoms
Symptom relief Recruiting nowThis study tests a computer program called C-SCAT that helps adolescents and young adults with cancer track and manage their symptoms. Participants use the tool to rate symptoms, find patterns, and plan how to cope. The goal is to see if using C-SCAT boosts their confidence and a…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Ancient herbal mix may ease constipation in cancer survivors
Symptom relief Recruiting nowThis study tests whether a traditional herbal formula called MZRW can help cancer survivors who suffer from constipation. Researchers will give 70 participants either MZRW or a placebo for two weeks and track bowel movements and gut bacteria changes. The goal is to see if MZRW is…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New study tests simple strategies to help cancer patients regain their sense of taste
Symptom relief Recruiting nowThis study looks at whether teaching cancer patients about taste changes caused by chemotherapy and giving them self-management tools can help reduce those symptoms and maintain healthy eating. About 400 adults starting chemotherapy will be split into two groups: one gets standar…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Kidney shield? new trial tests citrus compound for chemo patients
Symptom relief Recruiting nowThis study tests whether a combination of diosmin and hesperidin, natural compounds found in citrus fruits, can protect the kidneys of cancer patients receiving platinum-based chemotherapy. One hundred adults with confirmed cancer will take the supplement alongside their chemo to…
Phase: PHASE4 • Sponsor: Beni-Suef University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Dance your way to better sleep: latin moves tested in cancer survivors
Symptom relief Recruiting nowThis study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Art app may help cancer patients open up about distress
Symptom relief Recruiting nowThis study looks at whether a digital art activity can help cancer patients better express their distress, symptoms, and experiences. Researchers will enroll 60 adult cancer patients who are currently receiving treatment. Participants will use a digital tablet to create art and t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Mindfulness program aims to help cancer survivors kick smoking and cut alcohol
Symptom relief Recruiting nowThis study tests a 9-week mindfulness program (MBRP-SA) designed to help cancer survivors quit smoking and reduce heavy drinking. Six hundred participants in Florida will either get the mindfulness program plus nicotine patches or standard quitline support. The goal is to see if …
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New online program aims to ease anxiety in cancer survivors
Symptom relief Recruiting nowThis study is testing an online educational program called On-Trac to help adult cancer survivors cope with anxiety. The program teaches practical strategies based on well-known therapies like CBT and ACT. Researchers will measure changes in anxiety levels and emotional well-bein…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Walking and memory games may boost brain power in older cancer survivors
Symptom relief Recruiting nowThis study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
AI app aims to boost cancer Patients' mood and quality of life
Symptom relief Recruiting nowThis study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New program aims to ease menopause for young cancer survivors
Symptom relief Recruiting nowThis study is creating and testing a nurse-led program for women who experience early menopause after cancer. The program includes personalized education, decision support, and skills to manage menopause symptoms. About 117 women who have completed cancer treatment will take part…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Pre-Surgery breathing workouts may speed recovery after joint surgery
Symptom relief Recruiting nowThis study looks at whether doing breathing exercises before orthopedic surgery (like knee, hip, or fracture repair) can help your lungs work better after the operation. It involves 36 adults who have used tobacco and are at risk for breathing problems after surgery. Participants…
Phase: NA • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Palliative care clinic may boost security and cut ER visits for cancer patients
Symptom relief Recruiting nowThis study looks at whether having access to a specialized palliative care clinic helps cancer patients feel more secure and reduces unnecessary hospital visits. Researchers will compare patients who use the clinic with those who do not, and also ask family members about their ex…
Sponsor: Region Skane • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a psoriasis drug tame Immunotherapy's harsh side effects?
Symptom relief Recruiting nowThis pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…
Phase: PHASE1 • Sponsor: Brian Henick, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
One-Shot radiation hope for bulky tumors
Symptom relief Recruiting nowThis study tests a single, high-dose radiation treatment called spatially fractionated radiation (SFR) for people with large tumors (over 8 cm) or tumors that resist standard radiation. The goal is to see if one session can relieve symptoms as well as multiple sessions, with fewe…
Phase: NA • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Reiki for cancer fatigue: a new supportive therapy under study
Symptom relief Recruiting nowThis study tests whether Reiki, a gentle hands-on relaxation therapy, can help adults with cancer who feel very tired from immunotherapy. Twelve participants will either receive six weekly Reiki sessions right away or after a waiting period. Researchers will measure changes in fa…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
App and coach help young transplant patients shed pounds
Symptom relief Recruiting nowThis study is testing a weight loss program that uses a smartphone app and a coach to help teens and young adults who are overweight after a stem cell transplant. The goal is to see if the program can help them lose weight and build healthy eating habits. About 20 people who are …
Phase: NA • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New study aims to help cancer survivors ditch opioids for good
Symptom relief Recruiting nowThis study tests four different approaches—behavioral therapy, physical therapy, medication changes, and buprenorphine rotation—to help cancer survivors reduce their opioid use while keeping pain under control. It involves 294 veterans who have finished cancer treatment but still…
Phase: PHASE4 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Home workouts with live coaching could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether a 12-week personalized exercise program, done at home with a trainer guiding via video, can improve quality of life and reduce common side effects like fatigue, anxiety, and nerve pain in cancer survivors. About 350 adults who finished cancer treatment wi…
Phase: NA • Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Money stress and cancer: new study tests if monthly screening eases the burden
Symptom relief Recruiting nowThis study looks at whether asking people with advanced cancer about their financial struggles each month can help reduce their worry and improve their quality of life. About 1,000 adults receiving treatment for advanced or metastatic cancer will be randomly assigned to either mo…
Phase: NA • Sponsor: Alliance Foundation Trials, LLC. • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Blood cell harvest could fuel future immune disease cures
Knowledge-focused Recruiting nowThis study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
NIH launches Long-Term study to track stem cell transplant survivors
Knowledge-focused Recruiting nowThis study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Personalized care plans aim to boost resilience in seniors on chemo
Knowledge-focused Recruiting nowThis study looks at how to better support adults aged 65 and older during chemotherapy. Researchers will use a frailty score to create personalized care plans and track how well participants handle treatment. The goal is to see if this approach improves resilience and reduces hos…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Massive study aims to unravel mysteries of blood clots and vessel disease
Knowledge-focused Recruiting nowThis study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New robot arm takes on cancer surgery – first safety check begins
Knowledge-focused Recruiting nowThis study will test a new robotic surgery platform called RonovoTM in 40 adults with cancer who need elective surgery. The robot helps surgeons perform minimally invasive procedures in digestive, thoracic, urology, and gynecology areas. Researchers will track complications, tech…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Exercise may turn back the clock for blood cancer survivors
Knowledge-focused Recruiting nowThis study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…
Phase: NA • Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can lower doses of immunotherapy be safer without losing effectiveness?
Knowledge-focused Recruiting nowThis study looks at whether giving a lower dose of immunotherapy (pembrolizumab or nivolumab) causes fewer serious side effects than the standard higher dose. About 192 adults with solid tumors will be randomly assigned to receive either the higher or lower dose. The main goal is…
Phase: PHASE3 • Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Cancer survivors may carry hidden aging markers that raise disease risk
Knowledge-focused Recruiting nowThis study will compare levels of fatty acid binding proteins and cellular aging markers in 120 cancer survivors versus people who never had cancer. Researchers want to see if these markers are higher in survivors and linked to conditions like diabetes and high blood pressure. Pa…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New study aims to better understand what matters most to young cancer patients
Knowledge-focused Recruiting nowThis study asks 3000 teens and young adults (ages 15-39) with cancer, along with their caregivers, to answer survey questions about body image, fertility, and financial stress. The goal is to create better tools to measure quality of life for future patients. Participants include…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Thousands of cancer patients enrolled in massive immunotherapy observation study
Knowledge-focused Recruiting nowThis study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Massive proton therapy registry aims to unlock secrets of cancer treatment
Knowledge-focused Recruiting nowThis registry collects detailed information from cancer patients treated with proton radiation therapy. Researchers will track treatment plans, side effects, and quality of life over 15 years. The goal is to learn which patients benefit most from this precise form of radiation an…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New program aims to boost cancer trial enrollment from under 5%
Knowledge-focused Recruiting nowThis study tests a Clinical Trials Navigator program that helps cancer patients, families, and doctors find and enroll in clinical trials outside their local cancer centre. The program will be rolled out to 20 centres across Canada, starting with Thunder Bay and Winnipeg. Researc…
Phase: NA • Sponsor: Windsor Regional Hospital • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Could your genes hold the key to cancer risk? scientists investigate families
Knowledge-focused Recruiting nowThis study looks at genetic and behavioral factors that might influence cancer development and outcomes. It involves people with a personal or family history of cancer, who provide samples like blood, saliva, or urine. The goal is to better understand inherited cancer risks and f…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Cancer Patients' supplement use under the microscope
Knowledge-focused Recruiting nowThis observational study will survey 1,000 cancer patients about their use of dietary supplements like vitamins, minerals, and herbal products. Researchers want to know how common supplement use is, whether patients experience side effects, and if these supplements could interact…
Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood test may predict dangerous side effects of cancer immunotherapy
Knowledge-focused Recruiting nowThis observational study is looking at whether certain markers in the blood can predict immune-related side effects in cancer patients receiving immunotherapy. Researchers will collect blood samples and health data from 200 participants during routine visits. The goal is to bette…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New italian tool aims to ease MRI anxiety for cancer patients
Knowledge-focused Recruiting nowThis study is translating and testing an Italian version of a questionnaire that measures anxiety in cancer patients during whole-body MRI scans. Researchers will enroll 175 adult cancer patients at the European Institute of Oncology. The goal is to ensure the Italian version is …
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive cancer study aims to unlock tumor secrets and speed up trials
Knowledge-focused Recruiting nowSPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists launch study to unlock mysteries of rare bone diseases
Knowledge-focused Recruiting nowThis study aims to learn more about rare skeletal disorders by collecting medical records, blood samples, and genetic data from 100 participants. People with known or suspected bone conditions, as well as their healthy family members, can join either remotely or in person. The go…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can a smartwatch help track cancer symptoms? small study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Tiny study tracks cancer Drug's journey through the body
Knowledge-focused Recruiting nowThis early-stage study looks at how the experimental drug saruparib is absorbed, distributed, and eliminated in 8 people with advanced solid tumors. Participants will receive the drug by mouth and by vein, with samples taken to track the drug and its breakdown products. The goal …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Mayo clinic turns blood into stem cells to predict chemo side effects
Knowledge-focused Recruiting nowThis Mayo Clinic study is collecting blood samples from 30 cancer patients to create personalized stem cell models. The goal is to understand why some people have severe side effects from cancer therapy while others do not. This is a non-interventional study, meaning no new treat…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New PET imaging study aims to sharpen tumor detection
Knowledge-focused Recruiting nowThis study is collecting data from 2,000 adults with solid tumors who undergo theranostic PET scans as part of their routine care. The goal is to see how well these scans detect tumors and match with lab results, which could help doctors make better treatment decisions. Participa…
Sponsor: University Hospital, Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Cancer pill makeover may mess with treatment adherence
Knowledge-focused Recruiting nowThis study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape,…
Sponsor: Universidad Miguel Hernandez de Elche • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood cancer patients' journeys mapped over a decade
Knowledge-focused Recruiting nowThis study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study aims to spot lung trouble before it starts in transplant patients
Knowledge-focused Recruiting nowThis study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New toolkit aims to fix cancer trial diversity gap
Knowledge-focused Recruiting nowThis study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…
Phase: NA • Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple blood test predict who responds to immunotherapy?
Knowledge-focused Recruiting nowThis study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Decoding Immunotherapy's liver side effect to keep cancer treatment on track
Knowledge-focused Recruiting nowThis study looks at liver inflammation (hepatitis) that can occur in cancer patients treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers aim to describe the different patterns of liver injury and how they respond to treatment. By collecting real-world …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood cancer patients with penicillin allergy may get safer antibiotics
Knowledge-focused Recruiting nowThis study looks at whether we can safely remove the "beta-lactam allergy" label from blood cancer patients who are not truly allergic. By doing so, doctors can use more effective antibiotics. The study will enroll 3,800 hospitalized adults with blood cancers and a reported aller…
Phase: PHASE4 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Million-Patient study aims to unravel cancer fatigue mystery
Knowledge-focused Recruiting nowThis study will follow 1 million Chinese adults with cancer to measure how common and severe cancer-related fatigue is. Researchers will look at what factors influence fatigue and how it affects treatment and survival. The goal is to better understand this common but often overlo…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood protein clues could predict sepsis in cancer patients
Knowledge-focused Recruiting nowThis study looks at blood samples from 350 adults with blood cancer who develop a fever and have very low white blood cells (a condition called febrile neutropenia). The goal is to find patterns of proteins in the blood that can predict if a patient will develop serious complicat…
Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can your smartphone help fight cancer? new study aims to find out
Knowledge-focused Recruiting nowThis study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study aims to unravel cancer blood clot mysteries
Knowledge-focused Recruiting nowThis study is collecting blood and urine samples from 150 cancer patients who have had blood clots. The goal is to learn more about why clots happen in cancer and how to prevent them. Participants will be followed over time to track clot recurrence and bleeding risks.
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
5,000 cancer patients enrolled to uncover proton Therapy's hidden risks
Knowledge-focused Recruiting nowThis study is collecting information on side effects from proton therapy in 5,000 adults with many types of cancer. Researchers will track both short-term and long-term side effects and link them to the details of each patient's treatment plan. The goal is to better predict who m…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New program aims to bridge cancer care gaps for native americans
Knowledge-focused Recruiting nowThis study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …
Phase: NA • Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Coin flip chemo: study tests if patients will let a computer choose their treatment strength
Knowledge-focused Recruiting nowThis study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Can the flu vaccine protect kids with cancer? new study investigates
Knowledge-focused Recruiting nowThis study aims to understand how well the seasonal flu vaccine works in children with blood cancers like leukemia. Researchers will measure the immune response in up to 150 children at St. Jude Children's Research Hospital. The goal is to see if the vaccine triggers enough prote…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mayo clinic launches study to grow tumors in the lab
Knowledge-focused Recruiting nowThis study collects tumor tissue, blood, and cheek swabs from 50 adults with cancer to create personalized 3D models in the lab. Researchers will analyze the genetics and drug responses of these models to find new treatment targets. The goal is to improve understanding of aggress…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mayo clinic hunts for hidden cancer clues in DNA and proteins
Knowledge-focused Recruiting nowThis study looks at DNA and protein changes in tumor samples from 50 adults with aggressive or metastatic cancer. Researchers aim to find new markers for diagnosis and potential drugs. Participants provide blood, cheek swabs, and tissue from standard biopsies or surgeries.
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Massive study tracks lung disease progression in 4,000 patients
Knowledge-focused Recruiting nowThis study follows 4,000 people with interstitial lung disease (including conditions like pulmonary fibrosis and sarcoidosis) to understand how the disease naturally changes over time. Researchers will collect medical data and blood samples, and compare them to a healthy control …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused Recruiting nowThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
15-Year watch begins for CAR T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will check for long-term side effects and how well the treatment works over 15 years. No new treatment is given—just regular monitoring to meet safety guide…
Phase: PHASE3 • Sponsor: Lakefront Biotherapeutics NV • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Blood samples may reveal how to boost Cancer-Fighting immune cells
Knowledge-focused Recruiting nowThis study collects blood or apheresis samples from 24 people with solid tumors and healthy volunteers. Researchers will analyze immune cells to see how they respond to a neoantigen vaccine, which is designed to help the immune system recognize cancer. The goal is to learn how to…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Massive global study aims to uncover why young cancer patients in poorer nations fare worse
Knowledge-focused Recruiting nowThis study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…
Sponsor: Resonance, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
New PET tracer could light up tumors for better cancer imaging
Knowledge-focused Recruiting nowThis early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Scientists hunt for hidden cancer clues in families
Knowledge-focused Recruiting nowThis study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Tiny trial tracks leukemia Drug's journey through the body
Knowledge-focused Recruiting nowThis early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Albanian health scales get a scientific makeover
Knowledge-focused Recruiting nowThis study translates and tests several health questionnaires—covering pain, arm and leg function, mood, and daily activities—for use with Albanian-speaking people. Researchers will check if the translated versions are reliable and accurate by giving them to about 300 participant…
Sponsor: Universidad Católica San Antonio de Murcia • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Bone disease biobank launches to uncover hidden clues
Knowledge-focused Recruiting nowThis study is creating a collection of blood, urine, and leftover surgical tissue from 350 patients with bone, calcium, and growth plate disorders. The goal is to better understand how these diseases progress and to find markers that could predict outcomes. No new treatments are …
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New dashboard aims to reduce guesswork in muscle and joint care
Knowledge-focused Recruiting nowThis study tests a new tool called the PRISM Dashboard, which gives physiotherapists feedback on how their decisions compare to their peers. The goal is to see if this feedback helps reduce differences in care for people with muscle and joint pain. About 60 physiotherapists and t…
Phase: NA • Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Gut bacteria linked to cancer survivor symptoms?
Knowledge-focused Recruiting nowThis study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Can a simple tool give kids a voice in their own transplant care?
Knowledge-focused Recruiting nowThis study tests a new communication tool called 'Let's Get REAL' that helps children and teens (ages 8-17) and their families talk together about stem cell transplant or cellular therapy decisions. The goal is to see if the tool is easy to use and helpful for families. About 60 …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Can a website and a coach help cancer survivors plan End-of-Life care?
Knowledge-focused Recruiting nowThis study tests whether a patient navigator (a health coach) and a website called PACT help blood cancer survivors who had a stem cell transplant plan their future medical care. About 40 adults who are 1 to 5 years post-transplant will be assigned to usual care, the website, the…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Crushed cancer pill study aims to help kids who Can't swallow tablets
Knowledge-focused Recruiting nowThis study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New microscope peers inside living tumors to see how they behave
Knowledge-focused Recruiting nowThis study uses a special microscope called intravital microscopy to look at blood vessels inside solid tumors while patients are in surgery. Researchers want to see how these vessels work and how well they let blood and dye flow through. The goal is to learn whether tumor vessel…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer pain study tracks how opioids impact sleep and emotions
Knowledge-focused Recruiting nowThis study looks at 200 adults with moderate to severe cancer pain who are taking opioid painkillers like hydrocodone or oxycodone. Researchers will use smartwatches and questionnaires to track pain, sleep quality, and mood over three months. The goal is to understand how pain, i…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer gene study aims to unlock prognosis secrets
Knowledge-focused Recruiting nowThis study is collecting medical data and tumor or blood samples from 500 adults with malignant tumors treated at a Chinese hospital between 2017 and 2025. Researchers will analyze genes, immune cells, and other molecular features to understand what affects survival and treatment…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Pandemic's hidden toll: young cancer survivors under stress
Knowledge-focused Recruiting nowThis study looks at how the COVID-19 pandemic impacted the emotional, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors. Researchers will survey 600 participants to measure COVID-related distress and changes in health beh…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
40,000 cancer patients join quest for biomarkers
Knowledge-focused Recruiting nowThis study aims to build a large biobank of blood samples from 40,000 cancer patients to help identify biomarkers that can predict survival and response to treatment. Participants provide an extra 36ml of blood during routine blood draws. The samples will be used in future resear…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can exercise boost brain power in young cancer survivors?
Knowledge-focused Recruiting nowThis study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Patients help redesign clinical trials to boost diversity
Knowledge-focused Recruiting nowThis study aims to make clinical trials more inclusive by training 40 adults who are in remission from blood cancer to review and give feedback on trial plans. The goal is to see if this community-based review process is practical and acceptable. The study does not test a new tre…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study aims to improve drug dosing for stem cell transplant patients
Knowledge-focused Recruiting nowThis study looks at how a stem cell transplant changes a person's DNA and how that affects drug dosing. Researchers will collect blood, skin, hair, and other samples from 88 adults before and after transplant. The goal is to find the best way to test a patient's genes for safe an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
What do young cancer patients really need? this survey aims to find out
Knowledge-focused Recruiting nowThis study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
700-Patient study aims to unlock secrets of CAR-T success and failure
Knowledge-focused Recruiting nowThis study collects blood and tumor samples from 700 adults receiving approved CAR-T therapy for blood cancers. Researchers will analyze these samples to identify biological markers that predict whether the therapy will work or if the cancer will return. The goal is to improve fu…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New survey aims to give young cancer patients a stronger voice
Knowledge-focused Recruiting nowThis study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Gut bacteria may boost cancer immunotherapy: new trial launches
Knowledge-focused Recruiting nowThis study looks at how gut bacteria affect immunotherapy in people with advanced solid tumors. It has two parts: first, finding bacterial markers linked to treatment response; second, testing if fecal transplants from healthy donors can make immunotherapy work better. About 60 a…
Phase: NA • Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Lab tests on live tumor fragments could personalize cancer care
Knowledge-focused Recruiting nowThis study, led by Mayo Clinic, will take leftover tumor tissue from 250 cancer patients after surgery. Researchers will treat small fragments of the live tumor with different chemotherapy and immunotherapy drugs in the lab, monitoring responses over 72 hours. The goal is to see …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New program aims to boost health for cancer survivors in underserved communities
Knowledge-focused Recruiting nowThis study works with cancer survivors and their loved ones living in poor areas to improve their diet and physical activity. Researchers will adapt existing health programs to fit the community's needs. About 100 participants from the Birmingham area will track their eating, exe…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
What drives Parents' decisions in pediatric cancer trials? new study investigates
Knowledge-focused Recruiting nowThis study looks at the reasons parents consider when deciding whether to enroll their child in a cancer clinical trial. Researchers will survey and interview 400 parents of children newly diagnosed with cancer. The goal is to understand how social factors, personal preferences, …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Brain Radiation's hidden toll: new study tracks memory loss in blood cancer survivors
Knowledge-focused Recruiting nowThis study follows 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test memory, thinking, and quality of life over time using MRI scans and questionnaires. The goal is to understand how radiation affects the brain, not…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
QR wristband could speed up emergency care for chemo patients
Knowledge-focused Recruiting nowThis study is testing a new safety tool for cancer patients on chemotherapy. Patients wear a wristband with a QR code. If they go to the emergency room, doctors can scan the code and quickly fill out a checklist about possible serious side effects. The goal is to see if this help…
Sponsor: St Vincent's University Hospital, Ireland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Is a 1930s law blocking safe cancer info online? new survey investigates
Knowledge-focused Recruiting nowThis study uses anonymous surveys to ask cancer patients, healthcare professionals, and industry workers whether the UK's 1939 Cancer Act—which bans advertising cancer treatments to the public—still works in today's digital world. The goal is to understand how people use online a…
Sponsor: Royal Cornwall Hospitals Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New program helps young cancer survivors navigate parenthood decisions
Knowledge-focused Recruiting nowThis study is developing and testing a program to help female adolescent and young adult cancer survivors make informed decisions about building a family after treatment. The program includes four video sessions that provide personalized education about fertility risks and coping…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Can smart monitoring predict dangerous side effects in blood cancer treatment?
Knowledge-focused Recruiting nowThis study aims to find early signs that a patient is developing serious complications, like cytokine release syndrome, after immunotherapy for blood cancer. Researchers will track vital signs and immune responses in 100 adults receiving CAR-T or bispecific antibody therapy. The …
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Personalized cancer care: DNA profiling guides patients to best trials
Knowledge-focused Recruiting nowThis study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can what you eat during cancer treatment change your survival?
Knowledge-focused Recruiting nowThis study follows 1,538 cancer patients in China to see how their nutritional status affects how well they handle chemotherapy and radiation, their quality of life, and how long they live. Researchers will track changes in diet, weight, and blood markers over time. The goal is t…
Sponsor: Xiaoqin Luo • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can a simple home breathing test catch lung trouble early in transplant patients?
Knowledge-focused Recruiting nowThis study follows 250 people who have had a donor stem cell transplant to see if respiratory viruses lead to a lung condition called bronchiolitis obliterans syndrome (BOS). Participants use a handheld device at home to measure lung function and provide nasal swabs and blood sam…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC